ISPC Graph | iSpecimen Inc.

ISPC Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $151.94K; Cost of revenue $83.29K; Income tax (m); Net income -$1.36M.
2026-03-31: Revenue $156.01K; Cost of revenue $84.41K; Income tax (m); Net income -$2.28M.
2025-12-31: Revenue $51.76K*; Cost of revenue (m); Income tax (m); Net income -$5.00M*.
2025-09-30: Revenue $106.59K; Cost of revenue $204.59K; Income tax (m); Net income -$2.78M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Cost of revenue	Income tax	Net income
2026-06-30	$151.94K	$83.29K	(m)	-$1.36M
2026-03-31	$156.01K	$84.41K	(m)	-$2.28M
2025-12-31	$51.76K*	(m)	(m)	-$5.00M*
2025-09-30	$106.59K	$204.59K	(m)	-$2.78M
2025-06-30	$713.13K	$444.18K	(m)	-$1.05M
2025-03-31	$1.06M	$657.28K	(m)	-$1.66M
2024-09-30	$2.66M	$1.55M	(m)	-$1.44M
2024-06-30	$2.86M	$1.42M	(m)	-$2.11M
2024-03-31	$2.29M	(m)	(m)	-$2.90M
2023-09-30	$2.78M	$1.39M	(m)	-$2.11M
2023-06-30	$1.63M	$853.63K	(m)	-$3.48M
2023-03-31	$2.95M	$1.15M	(m)	-$2.43M
2022-09-30	$2.58M	$1.18M	(m)	-$3.10M
2022-06-30	$2.34M	$999.74K	(m)	-$2.61M
2022-03-31	$2.52M	$1.17M	(m)	-$2.38M
2021-09-30	$2.72M	$913.83K	(m)	-$1.55M
2021-06-30	$2.90M	$1.49M	(m)	-$1.39M
2021-03-31	$2.96M	$1.62M	(m)	-$3.96M
2020-09-30	$2.25M	$903.86K	(m)	-$1.25M
2020-06-30	$1.50M	$473.98K	-$145.00	-$174.09K
2020-03-31	(m)	(m)	(m)	-$1.64M

Revenue and expense 6 month

Period end	Revenue	Cost of revenue	Income tax	Net income
2026-06-30	$307.95K	$167.70K	(m)	-$3.64M
2025-06-30	$1.77M	$1.10M	(m)	-$2.71M
2024-06-30	$5.15M	(m)	(m)	-$5.01M
2023-06-30	$4.58M	$2.00M	(m)	-$5.92M
2022-06-30	$4.86M	$2.17M	(m)	-$4.99M
2021-06-30	$5.87M	$3.11M	(m)	-$5.36M
2020-06-30	$3.22M	$1.13M	-$145.00	-$1.81M

Revenue and expense 9 month

Period end	Revenue	Cost of revenue	Net income
2025-09-30	$1.88M	(m)	-$5.49M
2024-09-30	$7.82M	(m)	-$6.45M
2023-09-30	$7.35M	$3.39M	-$8.03M
2022-09-30	$7.44M	$3.35M	-$8.09M
2021-09-30	$8.59M	$4.03M	-$6.91M
2020-09-30	$5.47M	$2.03M	-$3.06M

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Income tax	Net income
2025-12-31	$1.93M	(m)	(m)	(m)	-$10.49M
2024-12-31	$9.29M	(m)	$1.49M	(m)	-$12.50M
2023-12-31	$9.93M	(m)	$1.62M	(m)	-$11.10M
2022-12-31	$10.40M	$4.76M	$1.47M	$0.00	-$10.25M
2021-12-31	$11.14M	$5.25M	$879.24K	$0.00	-$8.96M
2020-12-31	$8.18M	$3.59M	$319.24K	$0.00	-$4.65M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
FOXO TECHNOLOGIES INC. (FOXO)	United States	$0.000B	-277.71
OneMedNet Corp (ONMD)		$0.042B
bioAffinity Technologies, Inc. (BIAF)	United States	$0.063B
MAXCYTE, INC. (MXCT)	United States	$0.124B	-3.68
NRC HEALTH (NRC)	United States	$0.450B	42.50
OmniAb, Inc. (OABI)	United States	$0.698B	-8.05
Absci Corp (ABSI)	United States	$1.775B	-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)	United States	$14.060B	-43.97
Medpace Holdings, Inc. (MEDP)	United States	$17.316B	30.09
INCYTE CORP (INCY)	United States	$24.855B	13.14